Search Results - "van Riel, J.M.G"

Real-world and trial-based cost-effectiveness analysis of bevacizumab in HER2-negative metastatic breast cancer patients: a study of the Southeast Netherlands Breast Cancer Consortium by van Kampen, R.J.W, Ramaekers, B.L.T, Lobbezoo, D.J.A, de Boer, M, Dercksen, M.W, van den Berkmortel, F, Smilde, T.J, van de Wouw, A.J, Peters, F.P.J, van Riel, J.M.G, Peters, N.A.J.B, Tjan-Heijnen, V.C.G, Joore, M.A

“…Abstract Introduction The aim of our analysis was to assess the real-world cost-effectiveness of bevacizumab in addition to taxane treatment versus taxane…”
Get full text

Sixty-Day Mortality of Patients With Metastatic Colorectal Cancer Randomized to Systemic Treatment vs Primary Tumor Resection Followed by Systemic Treatment: The CAIRO4 Phase 3 Randomized Clinical Trial by van der Kruijssen, Dave E W, Elias, Sjoerd G, Vink, Geraldine R, van Rooijen, Karlijn L, 't Lam-Boer, Jorine, Mol, Linda, Punt, Cornelis J A, de Wilt, Johannes H W, Koopman, Miriam

“…The role of primary tumor resection (PTR) in synchronous patients with metastatic colorectal cancer (mCRC) who had unresectable metastases and few or absent…”
Get more information

A real-world study on implementation of bevacizumab in a cohort of HER2-negative metastatic breast cancer patients: A study of the Southeast Netherlands Breast Cancer Consortium by van Kampen, R.J.W., Lobbezoo, D.J.A., de Boer, M., Dercksen, M.W., Voogd, A.C., van den Berkmortel, F., Smilde, T.J., van de Wouw, A.J., Peters, F.P.J., van Riel, J.M.G., Peters, N.A.J.B., Peer, P.G.M., Joore, M.A., Tjan-Heijnen, V.C.G.

“…The objective of this study was to analyze real-world use and effectiveness of bevacizumab in combination with taxanes as first-line treatment in HER2-negative…”
Get full text